Epidermal Growth Factor Receptor-mediated Tissue Transglutaminase Overexpression Couples Acquired Tumor Necrosis Factor-related Apoptosis-inducing Ligand Resistance and Migration through c-FLIP and MMP-9 Proteins in Lung Cancer Cells

Treatment of metastatic breast cancer: second line and beyond

(2010) H. Roche et al.   ANNALS OF ONCOLOGY

Transglutaminase 2: A multi-tasking protein in the complex circuitry of inflammation and cancer

(2010) Kapil Mehta et al.   BIOCHEMICAL PHARMACOLOGY

Immunity, Inflammation, and Cancer

(2010) Sergei I. Grivennikov et al.   CELL

TRAIL receptor signaling and therapeutics

(2010) Junaid Abdulghani et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Inhibition of tissue transglutaminase sensitizes TRAIL-resistant lung cancer cells through upregulation of death receptor 5

(2010) Manuela Frese-Schaper et al.   FEBS LETTERS

A smac mimetic reduces TNF Related Apoptosis Inducing Ligand (TRAIL)-induced invasion and metastasis of cholangiocarcinoma cells

(2010) Christian D. Fingas et al.   HEPATOLOGY

Molecular basis for therapy resistance

(2010) Per E. Lønning   Molecular Oncology

EGF potentiated oncogenesis requires a tissue transglutaminase-dependent signaling pathway leading to Src activation

(2010) B. Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

TGM2 Is a Novel Marker for Prognosis and Therapeutic Target in Colorectal Cancer

(2009) Norikatsu Miyoshi et al.   ANNALS OF SURGICAL ONCOLOGY

Transglutaminase 2 expression levels regulate sensitivity to cystamine plus TRAIL-mediated apoptosis

(2009) Ji Hoon Jang et al.   CANCER LETTERS

Anti-Apoptotic Mechanisms of Drug Resistance in Cancer

(2009) T. Wilson et al.   CURRENT CANCER DRUG TARGETS

TRAIL receptor targeting therapies for non-small cell lung cancer: Current status and perspectives

(2009) J.H. Stegehuis et al.   DRUG RESISTANCE UPDATES

EGFR-directed therapies to treat non-small-cell lung cancer

(2009) Cheryl Ho et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Tissue Transglutaminase Is an Essential Participant in the Epidermal Growth Factor-stimulated Signaling Pathway Leading to Cancer Cell Migration and Invasion

(2009) Marc A. Antonyak et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Tissue Transglutaminase Regulates Matrix Metalloproteinase-2 in Ovarian Cancer by Modulating cAMP-response Element-binding Protein Activity

(2009) Minati Satpathy et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer

(2009) Kang-Seo Park et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study

(2009) Stephen Leong et al.   JOURNAL OF CLINICAL ONCOLOGY

Apoptosis and cancer: mutations within caspase genes

(2009) S Ghavami et al.   JOURNAL OF MEDICAL GENETICS

Acquired Activation of the Akt/Cyclooxygenase-2/Mcl-1 Pathway Renders Lung Cancer Cells Resistant to Apoptosis

(2009) W. Chen et al.   MOLECULAR PHARMACOLOGY

Luteolin, a Flavonoid with Potential for Cancer Prevention and Therapy

(2008) Yong Lin et al.   CURRENT CANCER DRUG TARGETS

Tumor resistance to apoptosis

(2008) Simone Fulda   INTERNATIONAL JOURNAL OF CANCER

Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells

(2008) X. Wang et al.   MOLECULAR CANCER THERAPEUTICS